A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.

Peter Bramlage Sascha René TittelSilvia MütherBirgit Reinhart-SteiningerHolger HaberlandSemik KhodaverdiStefan ZimnyUte OhlenschlägerStefanie LanzingerThomas Haak

Published in: Acta diabetologica (2022)

Insulin glulisine had comparable glucose control to lispro/aspart. The use of glulisine was less frequent in the present analysis compared to the previous trials.

Keyphrases

type diabetes
glycemic control
blood glucose
metabolic syndrome
blood pressure
skeletal muscle
insulin resistance
weight loss